No. The FDA reiterated its commitment to strong law enforcement. The agency has always placed higher priority
on legal violations that pose direct and significant safety risks to the public, but it does not minimize the importance of
enforcement against indirect health risks. The CGMP requirements are meant to prevent harm by building quality into
the design and production of pharmaceuticals.